Skip to content

Your Voice Matters

We’re working to improve your online healthcare experience. Want to help make it better? Submit your feedback or sign up for our research study and receive compensation for your time.

Find a Provider
Eran Tallis, M.D.

Eran Tallis, M.D.

Pediatrics, Pediatric Genetics

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Office (585) 275-5857
Administrative (585) 275-5857

Locations

Metabolic Genetics (Adult & Pediatric)

601 Elmwood Avenue, 1st Floor
Rochester, NY 14626

Get Directions
Pluta Cancer Center

125 Red Creek Drive
Rochester, NY 14623

Get Directions
Surgical Oncology

125 Red Creek Drive
Rochester, NY 14623

(585) 486-0600 Get Directions

About Me

Faculty Appointments

Assistant Professor - Department of Pediatrics, Genetics (SMD)

Assistant Professor - Department of Medicine, Genetics (SMD) - Joint

Credentials

Residency & Fellowship

Fellowship, Medical Biochemical Genetics, Baylor College of Medicine. 2021 - 2022

Residency, Baylor College of Medicine. 2019 - 2021

Fellowship, Reconstructive Urology & Genitourinary Cancer Survivorship, University of Texas MD Anderson Cancer Center. 2017 - 2019

Fellowship, Stem Cell Transplant, University of Texas MD Anderson Cancer Center. 2014 - 2017

Fellowship, Hematology, Chaim Sheba Medical Center (Israel). 2011 - 2014

Residency, Internal Medicine, Chaim Sheba Medical Center (Israel). 2006 - 2010

Education

MD | Hadassah Medical School (Israel). 2002

Awards

Clinical faculty award, special recognition award metabolic fellow. 2022

Publications

Journal Articles

Near-Haploid B-Cell Acute Lymphoblastic Leukemia in a Patient with Rubinstein-Taybi Syndrome.

Kurtz KJ, Tallis E, Marcogliese AN, Pulivarthi RH, Potocki L, Stevens AM

Pediatric hematology and oncology.. 2022 November 39 (8):747-754. Epub 03/11/2022.

Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma.

Lucari B, Tallis E, Sutton VR, Porea T

Pediatric hematology and oncology.. 2022 September 20 :1-7. Epub 09/20/2022.

Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment.

Tallis E, Karsenty CL, Grimes AB, Karam LB, Elsea SH, Sutton VR, Rawls-Castillo BL, Liu N, Soler-Alfonso C

JIMD reports.. 2022 July 63 (4):309-315. Epub 05/22/2022.

Evolution of germline TP53 variant classification in children with cancer.

Tallis E, Scollon S, Ritter DI, Plon SE

Cancer genetics.. 2022 June 264-265 :29-32. Epub 03/03/2022.

Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia.

Lu S, Tallis E, Ding X, Li D, Cox K, You MJ, St John L, Alatrash G, Ma Q, Molldrem JJ

Cytotherapy.. 2021 September 23 (9):793-798. Epub 06/30/2021.

Patient with mixed-phenotype acute leukemia with rearrangement.

Tallis E, Loghavi S, Jorgensen JL, Wang S, Khoury JD, Bueso-Ramos CB, Jain N, Borthakur G, Pemmaraju N

Leukemia & lymphoma.. 2019 November 60 (11):2829-2831. Epub 04/23/2019.

A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.

Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ

Cytotherapy.. 2016 August 18 (8):985-994. Epub 06/02/2016.

Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced.

Shimoni A, Shem-Tov N, Chetrit A, Volchek Y, Tallis E, Avigdor A, Sadetzki S, Yerushalmi R, Nagler A

Leukemia.. 2013 April 27 (4):829-35. Epub 10/17/2012.

In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus.

Tallis E, Rudensky B, Attias D, Raveh D, Schlesinger Y, Yinnon AM

Diagnostic microbiology and infectious disease.. 1999 October 35 (2):121-6. Epub 1900 01 01.